ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1984

Regulation of Multiple Differentiation Potential in Mesenchymal Stem Cells Via an Intercellular Ca2+ Signaling Pathway

Shuang Liu1, Erika Takemasa2 and Masaki Mogi2, 1Dept. Pharmacology,, Ehime University Graduate School of Medicine, Toon-shi, Japan, 2Pharmacology, Ehime University School of Medicine, Toon-shi, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Calcium and mesenchymal stem cells

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Title: Osteoarthritis and Joint Biology – Basic Science Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Multipotent mesenchymal stem cells (MSCs) are widely used in regenerative medicine to repair damaged tissues. Regulating Ca2+ release-activated Ca2+ (CRAC) channel-mediated intercellular Ca2+ signaling is critical to the functional modulation of MSCs. CRACM1 in the plasma membrane is an important molecular regulator of the CRAC channel. Our study aimed to elucidate the possible effects of CRAC channel regulation on the multiple differentiation potential of MSCs.

Methods: To increase Ca2+ influx, we overexpressed CRACM1 by transfecting PCDNA3-CRACM1 into MSCs (m1-MSCs). Genomic CRACM1-knockout MSCs (m1-ko-MSCs) were perpared using CRISPR/Cas9 technique. YM-58483 was used as a CRAC blocker. The inhibitory effect of YM-58483 was verified by imaging. Wild-type MSCs, m1-MSCs, m1-ko-MSCs, and YM-58483-treated MSCs were differentiated to adipocytes, osteocytes, or chondrocytes. Fatty acid-binding protein 4 was used as an adipocyte biomarker and osteocalcin was used for the detection of osteocytes. Aggrecan was used as a chondrogenic differential marker.

Results: The results sugges YM-58483 inhibited Ca2+ influx in MSCs in a dose-dependent manner, as demonstrated by Ca2+ imaging of fura-4-loaded cells. Downregulation of CRACM1 function in MSCs suppressed the differentiation of osteocytes, but not of adipocytes. A increase tendency on the potential of chondrogenic differentiation was observed in intracellular Ca2+-downregulated MSCs compared to wild-type MSCs. Overexpressing CRACM1 had no effect on the differentiation of osteocytes, but suppressed adipogenic and chondrogenic differentiation, while comparing with that observed in wild-type cells.

Conclusion: The results suggest that MSC differentiation potential is related to intercellular Ca2+ signaling pathways. In future study, we aim to research the systemic chondrocyte differentiation in vivo and, eventually, to carry out experiments in animal models to further contribute to the growing field of regenerative medicine.


Disclosure: S. Liu, None; E. Takemasa, None; M. Mogi, None.

To cite this abstract in AMA style:

Liu S, Takemasa E, Mogi M. Regulation of Multiple Differentiation Potential in Mesenchymal Stem Cells Via an Intercellular Ca2+ Signaling Pathway [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/regulation-of-multiple-differentiation-potential-in-mesenchymal-stem-cells-via-an-intercellular-ca2-signaling-pathway/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/regulation-of-multiple-differentiation-potential-in-mesenchymal-stem-cells-via-an-intercellular-ca2-signaling-pathway/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology